利伐沙班对预防肺癌相关肺血栓栓塞的研究进展
Research Progress of Rivaroxaban in Preventing Lung Cancer-Related Pulmonary Thromboembolism
DOI: 10.12677/ACM.2021.119601, PDF,   
作者: 杨玉婷, 杨 华*：湖北民族大学附属民大医院，湖北 恩施
关键词: 利伐沙班；肺癌；肺血栓栓塞症；预防；进展；Rivaroxaban； Lung Cancer； Pulmonary Thromboembolism； Prevention； Progress
摘要: 肺血栓栓塞症(pulmonary thromboembolism, PTE)是肺癌的严重相关并发症之一，也是肺癌患者死亡的主要原因之一。新型口服抗凝药利伐沙班，是国内上市最早的直接因子Xa抑制剂，相对于传统的低分子肝素及华法林预防具有更大的优势。基于此，本文将近年利伐沙班对预防肺癌相关PTE的研究进行总结，旨在为阐述利伐沙班在肺癌相关PTE中的预防地位优势及其临床医生用药提供参考。
Abstract: Pulmonary thromboembolism (PTE) is one of the serious related complications of lung cancer and one of the main causes of death in patients with lung cancer. Rivaroxaban, a new oral anticoagulant, is the earliest direct factor Xa inhibitor on the market in China, and has greater advantages over traditional low-molecular-weight heparin and warfarin prevention. Based on this, this article summarizes the research of rivaroxaban on the prevention of lung cancer-related PTE in recent years, and aims to provide a reference for elucidating the advantages of rivaroxaban in the prevention of lung cancer-related PTE and the use of drugs by clinicians.
文章引用：杨玉婷, 杨华. 利伐沙班对预防肺癌相关肺血栓栓塞的研究进展[J]. 临床医学进展, 2021, 11(9): 4120-4126. https://doi.org/10.12677/ACM.2021.119601

参考文献

[1] 杨欢欢, 陈虹. 肺癌合并肺栓塞的研究进展[J]. 中华结核和呼吸杂志, 2020, 43(7): 577-581.
[2] Panahi, L., Horseman, M., Weston, J., et al. (2021) Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina, 57, 110. [Google Scholar] [CrossRef] [PubMed]
[3] Grilz, E., Posch, F., Nopp, S., et al. (2021) Relative Risk of Arterial and Venous Thromboembolism in Persons with Cancer vs. Persons without Cancer—A Nationwide Analysis. European Heart Journal, 42, 2299-2307. [Google Scholar] [CrossRef] [PubMed]
[4] Becattini, C., Franco, L., Lee, A., et al. (2021) Treatment of Venous Thromboembolism in Cancer Patients: The Dark Side of the Moon. Cancer Treatment Reviews, 96, Article ID: 102190. [Google Scholar] [CrossRef] [PubMed]
[5] Moik, F., van Es, N., Posch, F., et al. (2020) Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Cancers, 12, 2493. [Google Scholar] [CrossRef] [PubMed]
[6] Joanna, R.S.S., Kim, A.S., Thapa, B., et al. (2021) Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. Med (N Y), 2, 423-434. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, W.W., Ning, S.W., et al. (2018) Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review. Journal of Cancer, 9, 3046-3057. [Google Scholar] [CrossRef] [PubMed]
[8] Guo, J., et al. (2019) Comparison among Different Presentations of Venous Thromboembolism Because of Lung Cancer. The Clinical Respiratory Journal, 13, 574-582. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, B., Zheng, Y., et al. (2020) Analysis on Risk Factors of Lung Cancer Complicated with Pulmonary Embolism. The Clinical Respiratory Journal, 15, 65-73. [Google Scholar] [CrossRef] [PubMed]
[10] Chaudhary, R., et al. (2020) Direct Oral Anticoagulants: A Review on the Current Role and Scope of Reversal Agents. Journal of Thrombosis and Thrombolysis, 49, 271-286. [Google Scholar] [CrossRef] [PubMed]
[11] Shnayder, N.A., Petrova, M.M., Shesternya, P.A., et al. (2021) Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines, 9, 451. [Google Scholar] [CrossRef] [PubMed]
[12] Iglesias, T.P.D. (2020) Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet? Current Treatment Options in Oncology, 21, 102-112. [Google Scholar] [CrossRef] [PubMed]
[13] Khorana, A.A., Liebman, H., Rosovsky, R., et al. (2021) Prediction and Prevention of Cancer-Associated Thromboembolism. The Oncologist, 26, e2-e7. [Google Scholar] [CrossRef] [PubMed]
[14] Margaret, C.F., Alan, S.G., Priya, A.P., et al. (2021) Anticoagulant Treatment Satisfaction with Warfarin and Direct Oral Anticoagulants for Venous Thromboembolism. Journal of Thrombosis and Thrombolysis.
[15] Goto, E., Ishimitsu, T. and Kato, T. (2020) Factor Xa Inhibitors in Clinical Practice: Comparison of Pharmacokinetic Profiles. Drug Metabolism and Pharmacokinetics, 35, 151-159. [Google Scholar] [CrossRef] [PubMed]
[16] Dunois, C. (2021) Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines, 9, 445. [Google Scholar] [CrossRef] [PubMed]
[17] Wu, T.T., Wu, L.S., Chen, W.J., et al. (2021) Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Neurology, 1-9.
[18] Spyropoulos, A.C., Ageno, W., Albers, G.W., et al. (2020) Post-Discharge Prophylaxis with Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology, 75, 3140-3147. [Google Scholar] [CrossRef] [PubMed]
[19] Wysokinski, W.E., Casanegra, A.I., Vlazny, D.T., et al. (2019) Comparison of Apixaban to Rivaroxaban and Enoxaparin in Acute Cancer-Associated Venous Thromboembolism. American Journal of Hematology, 94, 1185-1192. [Google Scholar] [CrossRef] [PubMed]
[20] 王声祥, 任艳平, 李楠, 等. 阿哌沙班、利伐沙班、达比加群酯、依诺肝素预防髋膝关节置换术后静脉血栓形成的成本-效果分析[J]. 中国医院药学杂志, 2020, 40(2): 208-212.
[21] Yagi, N., Nagai, K., Tanaka, T., et al. (2021) Current Status of Oral Anticoagulant Adherence in Japanese Patients with Atrial Fibrillation: A Claims Database Analysis. Journal of Cardiology. [Google Scholar] [CrossRef] [PubMed]
[22] Kuderer, N.M., Culakova, E., Lyman, G.H., et al. (2018) Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). The Oncologist, 23, 247-255. [Google Scholar] [CrossRef] [PubMed]
[23] Chiari, R., Landi, L., Morelli, A.M., et al. (2020) ROS1-Rearranged Non-Small-Cell Lung Cancer Is Associated with a High Rate of Venous Thromboembolism: Analysis from a Phase II, Prospective, Multicenter, Two-Arms Trial (METROS). Clinical Lung Cancer, 21, 15-20. [Google Scholar] [CrossRef] [PubMed]
[24] O’Connell, C., Goldhaber, S.Z., et al. (2021) Treatment of Cancer-Associated Venous Thromboembolism with Low- Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. The Oncologist, 26, e8-e16. [Google Scholar] [CrossRef] [PubMed]
[25] 马旭, 韩森, 方健. 肿瘤相关静脉血栓栓塞症中新型口服抗凝药应用进展[J]. 中华肿瘤防治杂志, 2021, 28(3): 237-242.
[26] Verso, M. and Di Nisio, M. (2020) Management of Venous Thromboembolism in Cancer Patients: Considerations about the Clinical Practice Guideline Update of the American Society of Clinical Oncology. European Journal of Internal Medicine, 71, 4-7. [Google Scholar] [CrossRef] [PubMed]
[27] 马军, 秦叔逵, 吴一龙, 等. 肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版) [J]. 中国肿瘤临床, 2019, 46(13): 653-660.
[28] Muñoz Martín, A.J., Escobar, I.G., Montero, R.M., et al. (2020) SEOM Clinical Guideline of Venous Thromboembolism (VTE) and Cancer (2019). Clinical and Translational Oncology, 22, 171-186. [Google Scholar] [CrossRef] [PubMed]
[29] 成伟丽, 陈媛, 李金凤. 利伐沙班配合低分子肝素对肺癌患者血栓发生率及凝血功能的影响观察[J]. 中国实验诊断学, 2020, 24(10): 1623-1626.
[30] Marshall, A., Hill, C., Hale, D., et al. (2020) Treatment of Cancer-Associated Venous Thromboembolism: 12-Month Outcomes of the Placebo versus Rivaroxaban Randomization of the SELECT-D Trial (SELECT-D: 12m). Journal of Thrombosis and Haemostasis, 18, 905-915. [Google Scholar] [CrossRef] [PubMed]
[31] Mantha, S., Miao, Y.M., Sarasohn, D.M., et al. (2017) Safe and Effective Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic Disease: A Prospective Cohort Study. Journal of Thrombosis and Thrombolysis, 43, 166-171. [Google Scholar] [CrossRef] [PubMed]
[32] Howlett, J., Fagnoni, P. and Quantin, C. (2020) Are Direct Oral Anticoagulants an Economically Attractive Alternative to Low Molecular Weight Heparins in Lung Cancer Associated Venous Thromboembolism Management? Journal of Thrombosis and Thrombolysis, 50, 642-651. [Google Scholar] [CrossRef] [PubMed]
[33] Khorana, A.A., Carrier, M., Meyer, G., et al. (2020) Prevention of Venous Thromboembolism in Ambulatory Patients with Cancer. ESMO Open, 5, E000948. [Google Scholar] [CrossRef] [PubMed]
[34] Riess, H., Weitz, J.I., et al. (2021) Treatment of Cancer-Associated Thrombosis: The Evolution of Anticoagulant Choice and Clinical Insights into Practical Management. Critical Reviews in Oncology/Hematology, 157, Article ID: 103125. [Google Scholar] [CrossRef] [PubMed]
[35] Duffett, L., et al. (2020) Pulmonary Embolism: Update on Management and Controversies. The BMJ, 370, m2177. [Google Scholar] [CrossRef] [PubMed]
[36] Zhang, X., Wang, X.H., Liao, K., et al. (2021) Current Use of Rivaroxaban in Elderly Patients with Venous Thromboembolism (VTE). Journal of Thrombosis and Thrombolysis, 1-9. [Google Scholar] [CrossRef] [PubMed]

为你推荐